Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tasimelteon next-day residual effects on driving
NCT06323655Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD) and jet lag disorder (3 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoint: Standard Deviation of Lateral Position at Day 1. Started Jul 2018; status: completed.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)jet lag disorder
Beyond the preview
Go deeper on NCT06323655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323655.